Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||G-protein-coupled receptors in drug discovery: nanosizing using cell-free technologies and molecular biology approaches|
|Citation:||Journal of Biomolecular Screening, 2005; 10(8):765-779|
|Publisher:||Mary Ann Liebert Inc Publ|
|Wayne R. Leifert, Amanda L. Aloia, Olgatina Bucco, Richard V. Glatz, and Edward J. Mcmurchie|
|Abstract:||Signal transduction by G-protein-coupled receptors (GPCRs) underpins a multitude of physiological processes. Ligand recognition by the receptor leads to activation of a genericmolecular switch involving heterotrimeric G-proteins and guanine nucleotides. Signal transduction has been studied extensively with both cell-based systems and assays comprising isolated signaling components. Interest and commercial investment in GPCRs in areas such as drug targets, orphan receptors, highthroughput screening, biosensors, and so on will focus greater attention on assay development to allow for miniaturization, ultra-high throughput and, eventually, microarray/biochip assay formats. Although cell-based assays are adequate for many GPCRs, it is likely that these formatswill limit the development of higher density GPCRassay platforms mandatory for other applications. Stable, robust, cell-free signaling assemblies comprising receptor and appropriate molecular switching components will form the basis of future GPCR assay platforms adaptable for such applications as microarrays. The authors review current cell-free GPCR assay technologies and molecular biological approaches for construction of novel, functional GPCR assays.|
|Keywords:||GPCR; G-proteins; HTS; cell-free; nanotechnology|
|Description:||© 2005 The Society for Biomolecular Screening|
|Appears in Collections:||Agriculture, Food and Wine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.